Leaflet: information for the user
Olmesartan/Amlodipine/Hydrochlorothiazide Normon 40 mg/5 mg/25 mg film-coated tablets
Olmesartan medoxomil/Amlodipine/Hydrochlorothiazide
Read this leaflet carefully before you start to take this medicine, because it contains important information for you.
This medicationcontains three active substances called olmesartan medoxomilo, amlodipine (as amlodipine besylate) and hydrochlorothiazide. The three substances help control high blood pressure.
The action of these substances contributes to lowering blood pressure. Olmesartan/Amlodipino/Hidroclorotiazida is used to treat high blood pressure:
Do not take Olmesartán/Amlodipino/Hidroclorotiazida Normon
Do not take olmesartán/amlodipino/hidroclorotiazida if any of these cases occur.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Olmesartán/Amlodipino/Hidroclorotiazida Normon:
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Olmesartán/Amlodipino/Hidroclorotiazida Normon. Your doctor will decide whether to continue treatment. Do not stop taking Olmesartán/Amlodipino/Hidroclorotiazida Normon in monotherapy.
Tell your doctorif you are taking any of the following medications used to treat high blood pressure (hypertension):
Your doctor may monitor your renal function, blood pressure, and electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Olmesartán/Amlodipino/Hidroclorotiazida Normon”.
Tell your doctorif you have any of the following health problems:
Contact your doctor if you experience any of the following symptoms:
Like any other medication that lowers blood pressure, excessive blood pressure reduction in patients with heart or brain blood flow abnormalities can cause a heart attack or stroke. Therefore, your doctor will closely monitor your blood pressure.
Olmesartán/amlodipino/hidroclorotiazida may cause an increase in lipid and uric acid levels in the blood. Your doctor will likely want to perform blood tests from time to time to monitor these possible changes.
You may experience changes in the levels of certain substances in your blood called electrolytes. Your doctor will likely want to perform blood tests from time to time to monitor this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, slow, tired, drowsy, or restless, nausea, vomiting, decreased need to urinate, rapid heart rate.Tell your doctor if you notice any of these symptoms.
If you are undergoing parathyroid function tests, you should stop taking olmesartán/amlodipino/hidroclorotiazida before the tests are performed.
It is reported to athletes that this medication contains a component that can establish a positive analytical result for doping control as positive.
Inform your doctor if you are pregnant (or think you may be). Olmesartán/amlodipino/hidroclorotiazida is not recommended for use at the beginning of pregnancy, and it should not be taken if you are more than 3 months pregnant, as it can cause severe damage to your baby if taken during this stage (see section “Pregnancy and breastfeeding”).
Children and adolescents (under 18 years)
Olmesartán/amlodipino/hidroclorotiazida is not recommended for use in children and adolescents under 18 years.
Olmesartán/Amlodipino/Hidroclorotiazida Normon with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any of the following medications:
Your doctor may need to modify your dose and/or take other precautions:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any of the following medications for:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Olmesartán/Amlodipino/Hidroclorotiazida Normon with food and drinks
Olmesartán/amlodipino/hidroclorotiazida can be taken with or without food.
People taking olmesartán/amlodipino/hidroclorotiazida should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice may cause an increase in the levels of the active ingredient amlodipino in the blood, which can cause an unpredictable increase in the effect of lowering blood pressure of olmesartán/amlodipino/hidroclorotiazida.
Be careful when drinking alcohol while taking olmesartán/amlodipino/hidroclorotiazida, as some people may feel dizzy, nauseous, or experience headaches. If this happens, do not drink any alcohol.
Older patients
If you are over 65 years old, your doctor will regularly monitor your blood pressure every time you increase the dose, to ensure that your blood pressure does not decrease too much.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant, or if you think you may be. Your doctor will advise you to stop taking olmesartán/amlodipino/hidroclorotiazida before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medication instead of olmesartán/amlodipino/hidroclorotiazida. Olmesartán/amlodipino/hidroclorotiazida is not recommended for use during pregnancy, and it should not be taken if you are more than 3 months pregnant, as it can cause severe damage to your baby if used from the third month of pregnancy.
If you become pregnant while taking olmesartán/amlodipino/hidroclorotiazida, inform and see your doctor immediately.
Lactation
Inform your doctor if you are breastfeeding or planning to start breastfeeding. It has been shown that amlodipino and hidroclorotiazida pass into breast milk in small amounts. Olmesartán/amlodipino/hidroclorotiazida is not recommended for use in mothers who are breastfeeding, and your doctor may choose another treatment if you wish to breastfeed.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machines
You may feel drowsy, nauseous, or experience headaches while taking medication for high blood pressure. If this happens, do not drive or operate machines until the symptoms have disappeared. Consult your doctor.
Olmesartán/Amlodipino/Hidroclorotiazida Normon contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”. The recommended dose is one tablet per day. Tablets can be taken with or without food. Take the tablets with a small amount of liquid (such as a glass of water). Do not chew the tablet. Do not take the tablets with grapefruit juice. Try to take your daily dose at the same time each day, for example, at breakfast time. If you take more Olmesartan/Amlodipino/Hidroclorotiazida Normon than you should If you take more tablets than you should, you may experience a drop in blood pressure, accompanied by symptoms such as dizziness, and a rapid or slow heart rate. If you take more tablets than you should or if a child accidentally ingests some tablets, contact your doctor immediately or go to the nearest emergency center and bring the medication packaging or this leaflet with you. Excess fluid may accumulate in the lungs (pulmonary edema) causing breathing difficulties that may develop up to 24-48 hours after ingestion. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20. If you forget to take Olmesartan/Amlodipino/Hidroclorotiazida Normon If you forget to take a dose, take the usual dose the next day. Do not take a double dose to make up for the missed doses. If you interrupt treatment with Olmesartan/Amlodipino/Hidroclorotiazida Normon It is essential to continue taking this medication, unless your doctor tells you to stop treatment. If you have any other questions about the use of this medication, ask your doctor or pharmacist. The following side effects may be serious: Unknown frequency: if you experience yellowish discoloration of the whites of the eyes, dark urine, skin itching, even if you started treatment with Olmesartan Normon some time ago,contact your doctor immediatelywho will evaluate your symptoms and decide how to continue treatment for high blood pressure. During treatment with olmesartan/amlodipine/hydrochlorothiazide, allergic reactions with facial, mouth, and/or laryngeal (vocal cords) inflammation, along with itching and skin rash, may occur.If this happens, stop taking this medication and consult your doctor immediately. Olmesartan/amlodipine/hydrochlorothiazide may cause a pronounced drop in blood pressure in susceptible patients. This can cause severe dizziness or fainting.If this happens, stop taking this medication, consult your doctor immediately, and remain lying down in a horizontal position. Decreased vision or eye pain may occur due to high blood pressure [possible signs of fluid accumulation in the vascular layer of the eye (choroidal hemorrhage) or acute angle-closure glaucoma]. Olmesartan/amlodipine/hydrochlorothiazide is a combination of three active substances. The following information, first, describes the side effects reported so far with the combination olmesartan/amlodipine/hydrochlorothiazide (in addition to those already mentioned) and, second, the known side effects of each of the active substances separately, or when two of the substances are taken together. To give you an idea of the number of patients who may experience side effects, they have been classified as frequent, infrequent, rare, and very rare. These are other side effects known so far with olmesartan/amlodipine/hydrochlorothiazide: If these side effects occur, they are often mild and do not require interrupting treatment. Frequent(may affect up to 1 in 10 people) Upper respiratory tract infection, sore throat, and nose, urinary tract infection, dizziness, headache, perception of heartbeats, low blood pressure, nausea, diarrhea, constipation, cramps, joint swelling, sensation of urgency to urinate, weakness, ankle swelling, fatigue, abnormal laboratory test results. Infrequent(may affect up to 1 in 100 people) Dizziness when standing up, vertigo, rapid heartbeat, sensation of fainting, flushing and sensation of heat in the face, cough, dry mouth, muscle weakness, inability to have or maintain an erection. These are the side effects known for each of the active substances separately or when two of the substances are taken together: They may be side effects due to olmesartan/amlodipine/hydrochlorothiazide, even if they have not been observed so far with olmesartan/amlodipine/hydrochlorothiazide. Very frequent(may affect more than 1 in 10 people) Edema (fluid retention). Frequent(may affect up to 1 in 10 people) Bronchitis, stomach and intestine infection, vomiting, increased blood sugar, sugar in urine, confusion, drowsiness, visual disturbances (including double vision and blurred vision), nasal secretion or congestion, sore throat, difficulty breathing, cough, abdominal pain, stomach burning, stomach discomfort, flatulence, joint or bone pain, back pain, bone pain, blood in urine, flu-like symptoms, chest pain, pain. Infrequent(may affect up to 1 in 100 people) Reduced number of a type of blood cell called platelets, which can cause easy bruising or prolong bleeding time, anaphylactic reactions, abnormal decrease in appetite (anorexia), sleep problems, irritability, mood changes including anxiety, sensation of depression, chills, sleep disorders, alteration of taste, loss of consciousness, decreased sense of touch, sensation of numbness, worsening of myopia, ringing in the ears (tinnitus), angina (chest pain or discomfort known as angina pectoris), irregular heartbeat, rash, hair loss, allergic skin inflammation, facial redness, purple patches or spots on the skin due to small hemorrhages (purpura), skin discoloration, itchy red patches (urticaria), increased sweating, pruritus, skin rash, skin reactions to light, such as sunburn or skin eruption, muscle pain, urination problems, sensation of needing to urinate at night, breast enlargement in men, decreased libido, facial swelling, feeling unwell, weight gain or loss, fatigue. Rare(may affect up to 1 in 1,000 people) Salivary gland inflammation and pain, decreased number of white blood cells in the blood, which could increase the risk of infections, decreased number of red blood cells (anemia), bone marrow damage, restlessness, sensation of loss of interest (apathy), seizures (convulsions), yellowish perception of objects when looking at them, dry eyes, blood clots (thrombosis, embolism), fluid accumulation in the lungs, pneumonia, inflammation of small blood vessels and skin, pancreatitis, yellowish discoloration of the skin and eyes, acute inflammation of the gallbladder, symptoms of lupus erythematosus such as skin rash, joint pain, and cold hands and fingers, severe skin reactions including intense skin eruption, urticaria, facial redness, severe itching, blisters, skin peeling, and inflammation, Stevens-Johnson syndrome, toxic epidermal necrolysis, sometimes very severe, movement impairment, acute kidney failure, non-infectious kidney inflammation, decreased kidney function, fever. Angioedema intestinal: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea. Very rare(may affect up to 1 in 10,000 people) High muscle tension, numbness of hands or feet, heart attack, stomach inflammation, gum thickening, intestinal obstruction, liver inflammation, acute respiratory distress (symptoms include severe difficulty breathing, fever, weakness, and confusion). Unknown frequency(cannot be estimated from available data) Decreased vision or eye pain (possible signs of acute angle-closure glaucoma). Tremors, rigid posture, mask-like face, slow movements, and unsteady gait with dragging feet. Skin and lip cancer (non-melanoma skin cancer). Reporting of side effects If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use:www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medication. Keep this medication out of the sight and reach of children. Do not use this medication after the expiration date that appears on the packaging and blister after “CAD.” The expiration date is the last day of the month indicated. Store below 30°C. Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and unused medicines at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medicines. By doing so, you will help protect the environment. The active principles are olmesartan medoxomil, amlodipine (as amlodipine besylate) and hydrochlorothiazide. Each film-coated tablet contains 40 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besylate) and 25 mg of hydrochlorothiazide. The other components are: Tablet core: pregelatinized maize starch, microcrystalline cellulose silicified, sodium croscarmellose, anhydrous colloidal silica and magnesium stearate. Tablet coating: polyvinyl alcohol, titanium dioxide (E-171), macrogol 4000, talc and yellow iron oxide (E-172). Olmesartán/Amlodipino/Hidroclorotiazida Normon 40 mg/5 mg/25 mg film-coated tablets are yellow, elliptical, biconvex tablets with the inscription “OA5” on one face and “H25” on the other. Olmesartán/Amlodipino/Hidroclorotiazida Normon film-coated tablets are presented in blister packs of 28 tablets. LABORATORIOS NORMON, S.A. Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN) The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/3. How to Take Olmesartan / Amlodipino / Hidroclorotiazida Normon
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
4. Possible Adverse Effects
5. Conservation of Olmesartan/Amlodipine/Hydrochlorothiazide Normon
6. Content of the packaging and additional information
Composition of Olmesartán/Amlodipino/Hidroclorotiazida Normon
Appearance of the product and content of the packaging:
Holder of the marketing authorization and responsible manufacturer
Date of the last review of this leaflet: February 2025
Other sources of information
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.